Interim report
Page 1
July 28, 2026 The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051. Symbol: RPGLIFE BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001. Scrip code: 532983 Dear Sir/Madam, Sub: Outcome of Board Meeting of the Company held on July 28, 2026. In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Tuesday, July 28, 2026, inter-alia considered and unanimously approved, the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, together with Limited Review Reports issued by the Statutory Auditors of the Company are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 03:00 p.m. and concluded at 6.30 p.m. Kindly take the same on record. Thanking you, Yours faithfully, For RPG Life Sciences Limited Rajesh Shirambekar Head – Legal & Company Secretary Encl.- as above L RPG LIFE SCIENCES RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: l24232MH2007PLC169354 An ~»RPG Company
Page 2
SR BC & COLLP Chartered Accountants 12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai -400 028, India Tel : +91 22 6819 8000 Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors RPG Life Sciences Limited I. We have reviewed the accompanying statement of unaudited standalone financial result of RPG Life Sciences Limited (the "Company") for the quarter ended June JO, 2026 (the "Statement") attached herewith, being submitted by the Company pur uant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) '·Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement i free of material misstatement. A review of interim tinancial information consists of making inquiries. primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable u to obtain a surance that we would become aware of all significant matter that might be identitied in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material mi statement. For S R B C & CO LLP Chartered Accountants ICAI Firm registration number: 324982E/E300003 per Aruna Kumaraswamy Partner Membership No.: 2 I 9350 UDIN: 2-~'2\9 350 E: 'U .. PEP b 13 / Place: Mumbai Date: July 28, 2026 S R BC & CO LLP, a limited liabiHty Partnership with LLP Identity No. AAB-4318 Regd. Office: 22, Camac Street. Block 'B', 3rd Floor, Kolkata-700 016
Page 3
£ RPO LIFE SCIENCES RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-69757100 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 I 2 3 4 5 6 7 8 9 10 II 12 13 14 Particulars Revenue from Operations Other Income (Refer note 3(a)) Total Income (1+2) Expenses (a) Cost of Materials Consumed (b) Purchases of Stock-in-Trade ( C) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade (ct) Employee Benefits Expense (e) Finance Cost (f-) Depreciation and Amortisation Expense (g) Other Expenses Total Expenses Profit before e·xceptional items and tax (3-4) Exceptional items (net) (Refer Note 3) Profit before tax Income tax expenses a. Current Tax b. Deferred Tax Total tax expenses Profit for the period (7-8) Other Comprehensive Income (i) Items that will not be reclassified to Profit or Loss (ii) Income tax relating to items that will not be reclassified to Profit or Loss Other Comprehensive Income/ (Loss) Net of Tax Total Comprehensive Income for the period (9+10) Paid-up Equity Share Capital (Face Value Rs. 8/-each) Other Equity Earnings per Share (of Rs. 8/-each) (not annualised for the quarter): (a) (b) Basic (in Rs.) Di luted ( in Rs.) SIGNED FOR IDENTIFICATION BY SR BC & CO LLP MUMBAI 30-06-2026 Unaudited 19,569 416 19,985 3,768 3,953 (906) 3.776 63 590 4,620 15,864 4,121 - 4,121 1,076 ( 12) 1,064 3,057 (20) 5 ( 15) 3,042 IJ23 18.49 18.49 (Rs. in Lakhs) Quarter ended Year ended 31-03-2026 30-06-2025 31-03-2026 Audited Unaudited Audited 17,689 16,892 70,752 1,236 523 2,554 18,925 17,415 73,306 3,643 3,204 13,598 2,263 3,306 13,810 153 (508) (2,199) 3,630 3,370 14,148 39 I 3 89 574 514 2,148 4,713 3,973 16,682 15,015 13,872 58,276 3,910 3,543 15,030 110 -390 4,020 3,543 15,420 721 907 3,475 309 7 428 l,o30 914 3,903 2,990 2,629 11,517 10 (2) (86) (2) I 22 8 (I) (64) 2,998 2,628 11,453 1,323 1,323 1,323 59,214 18.08 15.90 69.64 18.08 15.90 69.64 An ~»Rr'G Company
Page 4
£ RPG LIFE SCIENCES Notes: RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-69757100 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354 I. The above unaudited standalone financial results of the Company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on July 28, 2026. 2. The Company operates in only one reportable business segment i.e. Pharmaceuticals. 3. Exceptional items: (Rs. in Lakhs) Quarter ended Year ended Exceptional 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Income/ (Expenses) Unaudited Audited Unaudited Audited Net impact of Insurance claim on loss arising on account of 1,087 2,475 fire incident -Refer note 3(a) Impact of New Labour Codes -Refer note 3(b) (61) (1,169) Impairment of Intangible Assets Under Development (916) (916) (IAUD) -Refer note 3(c) Total exceptional items -Income 110 390 3(a) During tht: year ended March 31. 2026. the Company 1·ecc1ved rull settlement or the insurance cla11n relating to the !'ire incident at its Navi Mumb~i API plant which occurred in January 2025 The settlement re~ultccl in a net income or Rs 2,475 lakhs which 11-i~ recognized as E.\ceptional Inco111e in the respective quarters during FY26 when such claim proceeds were received. The Company had also recogn11.cd Rs. 791 lakhs received towards compensation for business interruption losses as Other income during the quarter ended March 31, 2026. 3(b) During the year ended March 31, 2026, the Company recognised an exceptional expense of Rs. I, 169 lakhs towards the impact of the New Labour Codes notilied effective November 22, 2025, primarily arising from the change in wage definition. The Company continues to monitor further regulatory developments and will account for any additional impact, if required. 3(c) Exceptional items for the quarter and year ended March 31, 2026 includes write-off of an int<)ngible asset under development. Based on management's annual assessme1it of impairment, no future economic benefits were expected to arise l"rom the project. According! 1, the accumulated costs incurred up to that date were written off and recognised as an exceptional item. 4. The Board of Directors of the Company, at its meeting held on December 15, 2025, approved the transfer of the API division ("the Division") of the Company, to its wholly owned subsidiary (WOS) viz. RPG Active Pharma Limited, which was incorporated on December 24, 2025, subject to receipt of all requisite consents The Company expects the transaction to be concluded upon receipt or the requisite approvals and completion or customary conditions precedent. 5. Figures or the quarter ended Mar h 31, 2026 are the balancing l1gure between audited figures in respect or the full l1nancial year and unaudited published year to elate 1·1gurc up to December 31, 2025 which were sub.1ccted to limned review by Auditors. Place: Mumbai Date July 28. 2026 SIGNED FOR IDENTIFICATION BY SR BC & CO LLP MUMBAI hlr Rl'C l.1lc Science~ l.1m1tccl Managing Director DIN 079067 I 0 An ~»Rir'G Company
Page 5
SR BC & COLLP Chartered Accountants 12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai -400 028, India Tel: +9122 6819 8000 Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors RPG Life Sciences Limited 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of RPG Life Sciences Limited (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30, 2026 (the ''Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations''). 2. The Holding Company's Management is responsihle !or the preparation or the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, ''Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants oflndia. 1 his Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain as urance that we would become aware of all significant matter that might be identified in an audit. Accordingly, we do not expres an audit opinion. We also performed procedure in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the subsidiary Company 'RPG Active Pharma Limited'. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules is ued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For S R B C & CO LLP Chartered Accountants ICAI Finn registration number: 324982E/E300003 ~ Partner Membership No.: 219350 UDIN: 2.b'2..\ q :>S-<:>\J,'.)-r?:f~ \/ 3112- Place: Mumbai Date: July 28, 2026 SR BC & CO LLP, a Limited Liability Partnership with LLP Identity No. AAB-4318 Regd. Office: 22, Camac Street, Block 'B'. 3rd floor, Koikata-700 016
Page 6
L RPO LIFE SCIENCES RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-69757100 Email: info@rpglifesciences.com www.rpglifesciences.com GIN: L24232MH2007PLC169354 _ STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUN,E 30, 2026 1 2 3 4 5 6 7 8 9 10 II 12 13 14 Particulars Revenue from Operations Other Income (Refer note 3(a)) Total Income (1+2) Expenses (a) Cost of Materials Co,isumed (b) Purchases of Stock-in-Trade ( C) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade (d) Employee Benefits Expense (e) Finance Costs (J) Depreciation and Amortisation Expense (g) Other Expenses Total Expenses Profit before exceptional items and tax (3-4) Exceptional items (net) (Refer Note 3) Profit before tax Income tax expenses a. Current Tax b. Deterred Tax Total tax expenses Profit for the period (7-8) Other Comprehensive Income (i) Items that will not be reclassified to Profit or Loss (ii) Income tax relating to items that will not be reclassified to Profit or Loss Other Comprehensive Income/ (Loss) Net of Tax Total Comprehensive Income for the period (9+ 10) Paid-up Equity Share Capital (Face Value Rs. 8/-each) Other Equity Earnings per Share (of Rs. 8/-each) (not annualised for the quarter): (a) (b) Basic (in Rs.) Diluted (in Rs.) SIGNED FOR IDENTIFICATION BY SR BC & CO LLP MUMBAI 30-06-2026 Unaudited 19,569 470 20,039 3,768 3,953 (906) 3,776 63 590 4,649. 15,893 4,146 - 4,146 1.082 ( 12) l,o70 3,076 (20) 5 ( I 5) 3,061 1_,323 18.60 18.60 (Rs. in Lakhs) Quarter ended Year ended 31-03-2026 30-06-2025 31-03-2026 Audited Unaudited Audited 17.689 16,892 70,752 1,240 523 2,558 18,929 17,415 73,310 3.643 3,204 13,598 2,263 3,306 13,810 153 (508) (2, I 99) 3,630 3,370 14,148 39 13 89 574 514 2,148 4,717 3 973 16,686 15,019 13,872 58,280 3,910 3,543 15,030 110 -390 4,020 3,543 15,420 721 907 3,475 309 7 428 l,o30 914 3,903 2,990 2,629 11,517 10 (2) (86) (2) I 22 8 (I) (64) 2,998 2,628 11,453 1,323 1,323 1,323 59,212 18.08 15.90 69.64 18.08 15.90 69.64 An ~»Rr'G Company
Page 7
RPG LIFE SCIENCES Notes: RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-69757100 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354 I. The above unaudited consolidated financial results of the Group have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on July 28, 2026. 2. The Group operates in only one reportable business segment i.e. Pharmaceuticals 3. Exceptional items: (Rs. in Lakhs) Exceptional Quarter ended Year ended 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Income/ (Expenses) Unaudited Audited Unaudited Audited Net impact of Insurance claim on loss arising on account of 1,087 2,475 fire incident -Refer note 3(a) Impact of New Labour Codes -Refer note 3(b) (61) ( 1.169) Impairment of lnrnngible Assets Under Development (\AUD) (916) (916) -Refer note](~) Total exceptional items -Income I 10 390 3(a) During the year ended March 31, 2026. the Group received full ettlemenl or the insurance claim relating to the l'ire incident al its Navi Mumbai API plant which occurred in January 2025. The settlement resulted in n net income of Rs. 2,475 lakhs which was recognized as Exceptional income in the respective quarters during FY26 when such claim proceeds were received The Group had also recognized Rs. 791 lakhs received towards compensation for business interruption losses as Other income during the quarter ended March 31. 2026 3(b) During the year ended March 31, 2026, the Group recognised an exceptional expense or Rs. I, 169 lakhs towards the impact or the New Labour Codes notified effective November 22, 2025, primarily arising fro111 the change in wage definition. The Group continues to monitor further regulatory developments and will account for any additional impact, if' required 3(c) Exceptional ite111s for the quarter and year ended March 31, 2026 includes write-off of an intangible asset under development. Based on management's annual assessmen.t of impairment, no future economic benefits were expected to arise from the project. Accordingly, the accumulated costs incurred up lo that date were wrillen off and recognised as an exceptional item. 4. The Board or Directors or the Com.pany, at its meeting held on December 15, 2025, approved the transfer or the API division ('"the Division") of the Company, to its wholly owned subsidiary (WOS) viz. RPG Active Pharma Limited, which was incorporated on Dece111ber 24, 2025, subject to receIpI of all requisite consents. The Group expects the transaction to be concluded upon receipt of the requisite approvals and completion or customary conditions precedent. 5 Figures o!' !he quart r ended March 31, 2026 are !he balancing figure between audited figures in respe ·t or the I·uII r111ancial year and unaudited published year to date figure up to December 31, 2025 which were subjected 10 limited review by Auditors. Place: Mumbai Date: July 28, 2026 SIGNED FOR IDENTIFICATION BY .-f\\C SR BC & CO LLP MUMBAI For RPG Life Sciences Limited Managing Director DIN 07906710 An ~»Rr'G Company